Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
My 10 Top Stocks to Buy to Start the New Year Off Right
03:15am, Thursday, 16'th Jan 2025
Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double digits. Investor enthusiasm about technology and growth stocks, and the econo
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
07:20pm, Wednesday, 15'th Jan 2025
CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic partne
CRISPR Therapeutics AG (CRSP) 43rd Annual JPMorgan Healthcare Conference - (Transcript)
07:39pm, Tuesday, 14'th Jan 2025
CRISPR Therapeutics AG (NASDAQ:CRSP ) 43rd Annual JPMorgan Healthcare Conference Call January 14, 2025 5:15 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conferenc
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
07:01pm, Tuesday, 14'th Jan 2025
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
04:34am, Tuesday, 14'th Jan 2025
If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock that could deliver huge gains in a defined time frame.
3 Mid-Cap Stocks That Could Take Off in 2025
04:20am, Thursday, 09'th Jan 2025
Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more modest valuations. Mid-cap stocks represent companies valued at between $2
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:30am, Wednesday, 08'th Jan 2025
ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
07:16pm, Tuesday, 07'th Jan 2025
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $41.92, moving -1.2% from the previous trading session.
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
08:46am, Tuesday, 07'th Jan 2025
Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA approval for the first CRSPR-based gene therapy treatment for sickle cell an
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
06:55pm, Tuesday, 31'st Dec 2024
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $39.36, denoting a +1.84% change from the preceding trading day.
Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025
12:56pm, Sunday, 29'th Dec 2024
Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 2024
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
07:06pm, Thursday, 26'th Dec 2024
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $41.07, representing a +0.32% change from its previous close.
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
08:50am, Monday, 23'rd Dec 2024
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.
This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?
12:25pm, Sunday, 22'nd Dec 2024
What's going on with CRISPR Therapeutics (CRSP 0.83%)? The company's shares have been southbound for the better part of three years.
1 big new Green Flag for CRISPR Therapeutics' Stock
09:30am, Friday, 20'th Dec 2024
CRISPR Therapeutics (CRSP -1.64%) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first commercialized therapy and a promising pipeline that's continuing to deliver
